Cargando…
Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment
BACKGROUND: Hepatocellular carcinoma (HCC) occurs rarely in children and adolescents (C&A), and its clinical characteristics, prognostic factors, and treatment were rarely explored. METHODS: This retrospective study focused on 65 HCC patients aged ≤20 years from August 1994 to August 2012. Cox r...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486687/ https://www.ncbi.nlm.nih.gov/pubmed/28397025 http://dx.doi.org/10.1007/s11605-017-3420-3 |
_version_ | 1783246308086120448 |
---|---|
author | Wang, Juncheng Mao, Yize Liu, Yongcheng Chen, Zhenxin Chen, Minshan Lao, Xiangming Li, Shengping |
author_facet | Wang, Juncheng Mao, Yize Liu, Yongcheng Chen, Zhenxin Chen, Minshan Lao, Xiangming Li, Shengping |
author_sort | Wang, Juncheng |
collection | PubMed |
description | BACKGROUND: Hepatocellular carcinoma (HCC) occurs rarely in children and adolescents (C&A), and its clinical characteristics, prognostic factors, and treatment were rarely explored. METHODS: This retrospective study focused on 65 HCC patients aged ≤20 years from August 1994 to August 2012. Cox regression models and Kaplan–Meier curves were used to investigate prognostic factors and compare overall survival (OS), respectively. RESULTS: We found 61.5% of patients to have multiple tumors, 30.8% to have portal vein tumor thrombus, and 16.9% to have distant metastasis. Diameter of tumors was 10.2 ± 4.1 cm. OS at 5 years was 15.8%. Multivariate analyses showed initial treatment (P < 0.001) to be a predictor for OS. For moderate-stage HCC, the median OS of patients who underwent resection was longer than that of patients who underwent transarterial chemoembolization (TACE) or supportive treatment (ST) (P < 0.001). For advanced-stage HCC, the median OS of patients who underwent TACE was longer than that of patients who underwent ST (P = 0.045). CONCLUSIONS: HCC in C&A tends to be more advanced than that in adults, and resection remains the mainstay of treatment for those patients. Moreover, compared with ST, TACE may benefit C&A with moderate- and advanced-stage HCC, which needs further study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11605-017-3420-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5486687 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-54866872017-07-11 Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment Wang, Juncheng Mao, Yize Liu, Yongcheng Chen, Zhenxin Chen, Minshan Lao, Xiangming Li, Shengping J Gastrointest Surg Original Article BACKGROUND: Hepatocellular carcinoma (HCC) occurs rarely in children and adolescents (C&A), and its clinical characteristics, prognostic factors, and treatment were rarely explored. METHODS: This retrospective study focused on 65 HCC patients aged ≤20 years from August 1994 to August 2012. Cox regression models and Kaplan–Meier curves were used to investigate prognostic factors and compare overall survival (OS), respectively. RESULTS: We found 61.5% of patients to have multiple tumors, 30.8% to have portal vein tumor thrombus, and 16.9% to have distant metastasis. Diameter of tumors was 10.2 ± 4.1 cm. OS at 5 years was 15.8%. Multivariate analyses showed initial treatment (P < 0.001) to be a predictor for OS. For moderate-stage HCC, the median OS of patients who underwent resection was longer than that of patients who underwent transarterial chemoembolization (TACE) or supportive treatment (ST) (P < 0.001). For advanced-stage HCC, the median OS of patients who underwent TACE was longer than that of patients who underwent ST (P = 0.045). CONCLUSIONS: HCC in C&A tends to be more advanced than that in adults, and resection remains the mainstay of treatment for those patients. Moreover, compared with ST, TACE may benefit C&A with moderate- and advanced-stage HCC, which needs further study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11605-017-3420-3) contains supplementary material, which is available to authorized users. Springer US 2017-04-10 2017 /pmc/articles/PMC5486687/ /pubmed/28397025 http://dx.doi.org/10.1007/s11605-017-3420-3 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Wang, Juncheng Mao, Yize Liu, Yongcheng Chen, Zhenxin Chen, Minshan Lao, Xiangming Li, Shengping Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment |
title | Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment |
title_full | Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment |
title_fullStr | Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment |
title_full_unstemmed | Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment |
title_short | Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment |
title_sort | hepatocellular carcinoma in children and adolescents: clinical characteristics and treatment |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486687/ https://www.ncbi.nlm.nih.gov/pubmed/28397025 http://dx.doi.org/10.1007/s11605-017-3420-3 |
work_keys_str_mv | AT wangjuncheng hepatocellularcarcinomainchildrenandadolescentsclinicalcharacteristicsandtreatment AT maoyize hepatocellularcarcinomainchildrenandadolescentsclinicalcharacteristicsandtreatment AT liuyongcheng hepatocellularcarcinomainchildrenandadolescentsclinicalcharacteristicsandtreatment AT chenzhenxin hepatocellularcarcinomainchildrenandadolescentsclinicalcharacteristicsandtreatment AT chenminshan hepatocellularcarcinomainchildrenandadolescentsclinicalcharacteristicsandtreatment AT laoxiangming hepatocellularcarcinomainchildrenandadolescentsclinicalcharacteristicsandtreatment AT lishengping hepatocellularcarcinomainchildrenandadolescentsclinicalcharacteristicsandtreatment |